ARGENX SE
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $ARGX in the last 30 days.
See all $ARGX insider activity →UBS assigned a Buy rating to Argenx SE, based on a weighted average of valuation, EPS revisions, and visibility metrics. The company's stock has seen a 0.66% increase over 5 days and a 7.97% rise year-to-date.
Guggenheim reaffirmed a Buy rating on argenx with a $1120 price target, suggesting 43% upside from the Oct 22 close. The firm cited strong Vyvgart sales of $1.72B, up 14% QoQ and 53% YoY, and a promising pipeline as reasons for its outlook.
Argenx SE received a Buy rating from DZ Bank and a Neutral rating from Deutsche Bank. The company's stock is currently trading at 788.20 EUR, with a 5-day change of +0.61%, a 1st Jan change of +8.16%, and a year-to-date change of +9.79%. The ratings are based on various composite factors including valuation, EPS revisions, and visibility.
Over the past 7 days, AlphAI's AI scored 26 news stories mentioning ARGX (ARGENX SE). Coverage has skewed bullish: 15 bullish, 2 neutral, and 9 bearish.
Recent ARGX coverage spans financial news, earnings and market movers.
UBS assigned a Buy rating to Argenx SE, based on a weighted average of valuation, EPS revisions, and visibility metrics. The company's stock has seen a 0.66% increase over 5 days and a 7.97% rise year-to-date.
Analyst rating and higher price target could attract buying interest.
Argenx SE received a Buy rating from DZ Bank and a Neutral rating from Deutsche Bank. The company's stock is currently trading at 788.20 EUR, with a 5-day change of +0.61%, a 1st Jan change of +8.16%, and a year-to-date change of +9.79%. The ratings are based on various composite factors including valuation, EPS revisions, and visibility.
Analyst downgrade may pressure the stock as investors reassess valuation.
Earnings beat and strong pipeline suggest upside pressure.
AlphAI scores every news story that mentions ARGX with an AI model for sentiment and relevance, and aggregates insider trades from ARGENX SE's SEC EDGAR Form 4 filings. Figures refresh continuously.
UBS assigned a Buy rating to Argenx SE, based on a weighted average of valuation, EPS revisions, and visibility metrics. The company's stock has seen a 0.66% increase over 5 days and a 7.97% rise year-to-date.
1 min readGuggenheim reaffirmed a Buy rating on argenx with a $1120 price target, suggesting 43% upside from the Oct 22 close. The firm cited strong Vyvgart sales of $1.72B, up 14% QoQ and 53% YoY, and a promising pipeline as reasons for its outlook.
1 min readArgenx SE received a Buy rating from DZ Bank and a Neutral rating from Deutsche Bank. The company's stock is currently trading at 788.20 EUR, with a 5-day change of +0.61%, a 1st Jan change of +8.16%, and a year-to-date change of +9.79%. The ratings are based on various composite factors including valuation, EPS revisions, and visibility.
1 min readWells Fargo lowered Argenx's price target to $1,336 from $1,356, maintaining an Overweight rating. The firm expects positive December data to drive a re-rating. CoreWeave shares fell 1% after a 10% drop, while Nokia rose 4.5% on strong AI-related sales. CoreWeave faces financing concerns, while Nokia shows AI growth.
2 min readargenx reported Q3 2026 revenue of $1.721B, up 54% YoY, exceeding expectations. The company plans up to 5 launches in 2027, expanding into rheumatology and gastroenterology. Cash position is $3.7B, with strong profitability and growth investments.
3 min readARGENX SE (ARGX) furnished an SEC Form 6-K — earnings release. argenx Reports Third Quarter 2026 Financial Results and Provides Business Update Continued strong VYVGART performance drives $1.7 billion in global product net sales, representing 54% year-over-year growth and 13% quarter-over-quarter growth sBLA for VYVGART Hytrulo in IMNM on tr
3 min readargenx (ARGX) reported Q3 2026 sales of $1.7B, up 54% YoY, with net profit of $506M. FDA granted priority review for VYVGART Hytrulo, with a PDUFA date set for February 2027. The company also announced positive Phase 3 results for VYVGART in IMNM and dermatomyositis, and plans to file an sBLA for IMNM by year-end. ARGX closed the Forte Biosciences deal, spending about $2.1B, and has cash of near $3.7B as of September 30, 2026.
2 min readargenx reported Q3 EPS of $7.80, up from $5.18 a year earlier, with product net sales rising 53% to $1.72B. The company expects combined R&D and SG&A expenses to total around $4B in 2026, including Forte Biosciences-related costs.
1 min readArgenx (AGNX) stock rose 4.99% to €766.20 after Oddo BHF increased its price target to €875, indicating 14% upside potential. The company's ALKIVIA study met its primary endpoint, and Q3 results are due October 22. The stock trades below its 20-day and 50-day moving averages but above the 200-day.
2 min readTD Cowen reiterated a Buy rating and $1,353 price target for argenx SE (ARGX), expecting Q3 revenue to beat consensus estimates. The biotech company showed 70% revenue growth over the last year. Analysts anticipate CIDP market share growth and Phase 3 MMN data as key catalysts. Recent analyst updates include mixed price target adjustments and ratings.
2 min read
